Kan He
Impact in
- Biomaterials top 10%
- Nanoparticle-Based Drug Delivery
-
- MicroRNA in disease regulation
Papers in
-
- Advanced biosensing and bioanalysis techniques 2
- Metabolomics and Mass Spectrometry Studies 2
-
- Berberine and alkaloids research 4
- Inflammatory mediators and NSAID effects 2
- Co-authors
- Dan Shao (12 shared papers)Xiao Zheng (10 shared papers)Li Chen (11 shared papers)Yawei Zhao (11 shared papers)Lianzhi Cui (6 shared papers)Madi Sun (6 shared papers)Yinghui Huang (2 shared papers)Ying‐Hua Jin (2 shared papers)
- Journals
- Biomaterials (3 papers)OncoTargets and Therapy (2 papers)Molecular Carcinogenesis (1 paper)British Journal of Cancer (1 paper)Aging (1 paper)
- Partner nations
- ChinaUnited StatesNepal
In The Last Decade
Kan He
20 papers receiving 659 citations
Peers
Comparison fields: 5 of 84
- Biomaterials 141
- Cancer Research 112
- Pharmacology 61
- Pharmacology 110
- Molecular Biology 319
Countries citing papers authored by Kan He
This map shows the geographic impact of Kan He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kan He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kan He more than expected).
Fields of papers citing papers by Kan He
This network shows the impact of papers produced by Kan He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kan He. The network helps show where Kan He may publish in the future.
Co-authors
The 25 scholars most cited alongside Kan He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 132 | |
| 2 | 2010 | 96 | |
| 3 | 2021 | 76 | |
| 4 | 2019 | 54 | |
| 5 | 2018 | 47 | |
| 6 | 2017 | 45 | |
| 7 | 2018 | 33 | |
| 8 | 2023 | 29 | |
| 9 | 2020 | 28 | |
| 10 | 2019 | 28 | |
| 11 | 2017 | 24 | |
| 12 | 2021 | 19 | |
| 13 | 2018 | 10 | |
| 14 | 2012 | 10 | |
| 15 | 2021 | 10 | |
| 16 | 2021 | 9 | |
| 17 | 2019 | 6 | |
| 18 | 2024 | 2 | |
| 19 | 2025 | 2 | |
| 20 | 2023 | 2 |
About Kan He
Kan He is a scholar working on Molecular Biology, Pharmacology, Oncology, Immunology and Cancer Research, having authored 20 papers that have together received 662 indexed citations. Recurring topics across this work include Berberine and alkaloids research (4 papers), Advanced biosensing and bioanalysis techniques (2 papers), MicroRNA in disease regulation (2 papers), Osteoarthritis Treatment and Mechanisms (2 papers), Nanoparticle-Based Drug Delivery (2 papers), Metabolomics and Mass Spectrometry Studies (2 papers), Inflammatory mediators and NSAID effects (2 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Biomaterials (141 citations), Cancer Research (112 citations), Pharmacology (61 citations), Pharmacology (110 citations) and Molecular Biology (319 citations). Kan He has collaborated with scholars based in China, United States and Nepal. Frequent co-authors include Dan Shao, Xiao Zheng, Li Chen, Yawei Zhao, Lianzhi Cui, Madi Sun, Yinghui Huang, Ying‐Hua Jin, Yong Jia and Li Yang. Their work appears in journals such as Biomaterials, OncoTargets and Therapy, Molecular Carcinogenesis, British Journal of Cancer and Aging.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.